Roquefort Therapeutics plc
LSE ROQ.L
Roquefort Therapeutics plc Return on Assets (ROA) for the year ending December 31, 2023
Roquefort Therapeutics plc Return on Assets (ROA) is NA for the year ending December 31, 2023. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.
Key data
| Date | Return on Assets (ROA) | Return on Equity (ROE) | Return on Capital Employed (ROCE) | Interest Coverage Ratio |
|---|
Market news
Loading...
Don’t Miss A Beat
LSE: ROQ.L
| CEO | Mr. Trevor Ajanthan Reginald |
| IPO Date | March 22, 2021 |
| Location | United Kingdom |
| Headquarters | Eccleston Yards |
| Employees | 10 |
| Sector | Healthcare |
| Industries | |
Description
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Key trends
Past 5 years
StockViz Staff
February 6, 2025
Any question? Send us an email